TY - JOUR
T1 - Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules
AU - Mouri, Akihiro
AU - Nagai, Taku
AU - Ibi, Daisuke
AU - Yamada, Kiyofumi
N1 - Funding Information:
This study was supported in part by Grants-in-Aid for Scientific Research (nos. 22390046 , 23790081 , 23791325 ) from JSPS; “Integrated research on neuropsychiatric disorders” from MEXT; Academic Frontier Project for Private Universities , matching fund subsidy from MEXT, 2007–2011; Takeda Science Foundation ; the MEXT Global-COE Program ; and CREST from JST.
PY - 2013/5
Y1 - 2013/5
N2 - Schizophrenia is a severe and common psychiatric disease with a lifetime prevalence of 0.5% to 1% globally. Because of limitations of the experimental approach in humans, valid animal models are essential in the effort to identify novel therapeutics for schizophrenia. In most animal models of schizophrenia, second generation antipsychotic drugs are reported to be effective in ameliorating behavioral abnormalities, while clinical evidence indicates that some of the patients are resistant to the antipsychotic drug therapy. Accordingly, animal models of antipsychotic drug-resistant schizophrenia are needed for screening of novel agents that may be more effective than the existing antipsychotic drugs. Furthermore, utilization of appropriate behavioral tasks with reference to human testing is essential to facilitate the development of novel pharmacotherapeutic approaches for the treatment in schizophrenia. Experimental data suggest that there are different types of potential candidate molecules as novel antipsychotic drugs with some therapeutic effects on negative symptoms and cognitive deficits in schizophrenia. It is proposed that to develop novel antipsychotic drugs the efficacy of potential candidate molecules should be evaluated using animal models for treatment-resistant schizophrenia with appropriate behavioral tasks in reference to human testing.
AB - Schizophrenia is a severe and common psychiatric disease with a lifetime prevalence of 0.5% to 1% globally. Because of limitations of the experimental approach in humans, valid animal models are essential in the effort to identify novel therapeutics for schizophrenia. In most animal models of schizophrenia, second generation antipsychotic drugs are reported to be effective in ameliorating behavioral abnormalities, while clinical evidence indicates that some of the patients are resistant to the antipsychotic drug therapy. Accordingly, animal models of antipsychotic drug-resistant schizophrenia are needed for screening of novel agents that may be more effective than the existing antipsychotic drugs. Furthermore, utilization of appropriate behavioral tasks with reference to human testing is essential to facilitate the development of novel pharmacotherapeutic approaches for the treatment in schizophrenia. Experimental data suggest that there are different types of potential candidate molecules as novel antipsychotic drugs with some therapeutic effects on negative symptoms and cognitive deficits in schizophrenia. It is proposed that to develop novel antipsychotic drugs the efficacy of potential candidate molecules should be evaluated using animal models for treatment-resistant schizophrenia with appropriate behavioral tasks in reference to human testing.
UR - http://www.scopus.com/inward/record.url?scp=84875109921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875109921&partnerID=8YFLogxK
U2 - 10.1016/j.nbd.2012.10.025
DO - 10.1016/j.nbd.2012.10.025
M3 - Review article
C2 - 23142533
AN - SCOPUS:84875109921
SN - 0969-9961
VL - 53
SP - 61
EP - 74
JO - Neurobiology of Disease
JF - Neurobiology of Disease
ER -